Medical body’s legal battle with trade union continues
Business Day 22 March 2021 - Dispute between the SA Medical Association and
the SA Medical Association Trade Union is about deductions, which the union
claims belong to it
A judgment handed
down by the Constitutional Court last week did not mean that the non-profit
professional body representing medical doctors and medical students was
required to immediately pay millions of rand to the trade union representing
doctors in the public sector, it said on Friday. The SA Medical Association
(Sama) and the SA Medical Association Trade Union (Samatu) have been in a
long-standing dispute over whether Sama owes Samatu millions of rand in
deductions paid over the past 20 years. Samatu, which is under administration,
has applied for Sama’s liquidation saying that it owes as much as R370m, but
Sama is opposing this.
Boris Johnson tries to defuse vaccine tension with EU
Business Day 22 March 2021 - Prime minister says he feels reassured after
talks with European partners over several months that they do not want to see
vaccine blockades
British Prime Minister Boris Johnson has said the EU does not want to launch a vaccine battle, despite the bloc warning it is set to restrict exports of coronavirus shots to the UK. In an attempt to defuse the tensions with Brussels, Johnson said avoiding blockades of vaccine supplies is vital because immunisation programmes require countries to work together. The comments underline his government’s position that the EU should keep to its earlier promises not to get in the way of exports to the UK. The tone he struck was conciliatory even as political tempers flared.
AstraZeneca vaccines sale concluded, says health ministry
Business Day 22 March 2021 - The sale became necessary once SA decided to
pivot to the Johnson & Johnson vaccine study
SA has sold the
AstraZeneca vaccines it had initially planned to roll out to South Africans,
the ministry of health said on Sunday, emphasising that the money for the
transaction had been received. The ministry said in a statement health minister
Zweli Mkhize was pleased to announce that the sale of the AstraZeneca vaccines
SA had acquired had been concluded. The announcement came a day before Reuters
reported on Monday that the AstraZeneca and Oxford University's
coronavirus vaccine received a major boost as data from a large trial showed it
was safe and effective.
AU urges states to continue use of AstraZeneca vaccine
Business Day 18 March 2021 - Recommendation comes several European countries
suspended use of the AstraZeneca shots
he AU said on
Thursday that African countries should continue to use AstraZeneca's Covid-19
vaccine, echoing the World Health Organization (WHO) by saying the shot's
benefits outweighed risks. The recommendation comes after several European
countries suspended use of the AstraZeneca vaccine amid concerns over the risk
of blood clots. Africa has lagged wealthier parts of the world in vaccinations,
with many countries on the continent using free AstraZeneca shots distributed
by a global scheme co-led by the WHO to kick-start immunisation campaigns.
UK says SII vaccine delays add to supply squeeze
Business Day 18 March 2021 - The Serum Institute of India, which makes the
AstraZeneca shot, says it will supply more based on the needs of the vaccine
programme in India
Britain is facing a squeeze on supply of Covid-19 vaccines in April in part due to a delay in a shipment from the Serum Institute of India (SII) that makes AstraZeneca’s shot, health minister Matt Hancock said on Thursday. Britain has been conducting the fastest rollout of inoculations by a major economy but health officials said on Wednesday that the programme would face a significant reduction in supplies from March 29, without initially specifying where the problems were.
Should we be worried about blood clots and AstraZeneca’s vaccine?
Business Day 18 March 2021 - Probably not, as there are only 30 reported
cases from more than 17-million doses of the vaccine being given in the UK and
EU
Europe’s drug
watchdog is reviewing a small number of reports of bleeding, blood clots and
low platelet counts in people who have received AstraZeneca’s coronavirus
vaccine. The European Medicines Agency (EMA) has said it has so far found no
causal link between the vaccine and the incidents. The World Health
Organization (WHO) has also said there is no proven link and people should not
panic. At least 13 EU member states including Germany, France, Italy have
suspended use of the shot pending the outcome of the EMA’s probe.
State-backed Biovac clinches deal with ImmunityBio to make Covid-19 vaccines
Business Day 18 March 2021 - If the phase 1 trial demonstrates the vaccine
elicits a response, larger phase 2 and 3 trials will be conducted during the
year
State-backed vaccine
manufacturer Biovac has entered into a partnership with California-based
ImmunityBio for local production of its candidate Covid-19 vaccine, it
announced on Thursday. The agreement is strategically important because it
paves the way for Biovac to develop the expertise to manufacture active
pharmaceutical ingredients (APIs), said CEO Morena Makhoana. There is currently
no vaccine API production in SA, and local pharmaceutical manufacturers, such
as Biovac and Aspen Pharmacare, fill and package vaccines formulated by other
firms. “Strategically, if we want to make a long-term impact, we have to look
at API manufacturing,” said Makhoana. Biovac anticipated building the capacity
to produce vaccine APIs for both the domestic and export market, he said.
SAHPRA approves emergency use application for Pfizer vaccine
Medical Brief 17 March 2021 - South Africa‘s drugs regulator SAHPRA has
announced that it had approved a conditional “section 21” emergency use
application for the COVID-19 vaccine developed by Pfizer and BioNTech.
SAHPRA added that
the approval was subject to further efficacy and safety surveillance of the
vaccine in the country, including monitoring its efficacy against the dominant
local coronavirus variant. South Africa is the hardest-hit country on the
African continent in terms of recorded coronavirus cases and deaths and
suffered a severe second wave of infections driven by the more infectious
501Y.V2 variant, first identified late last year.
Sinovac offers 5-million coronavirus vaccines to SA
Business Day 17 March 2021 - The CoronaVac shot has not yet been approved in
SA, but if it is, delivery could come within weeks
Chinese
coronavirus vaccine manufacturer Sinovac Biotech has offered to supply the government
with 5-million doses of its CoronaVac shot, which could be provided within
weeks, its local partner Numolux said. Chinese coronavirus vaccine manufacturer
Sinovac Biotech has offered to supply the government with 5-million doses of
its CoronaVac shot, which could be provided within weeks, its local partner
Numolux said. Sinovac’s vaccine requires two doses, administered two weeks
apart.
No room for corruption in vaccine procurement and rollout, says Mabuza
Business Day 17 March 2021 - There is limited room for corruption
in the acquisition and rollout of the Covid-19 vaccines, deputy president David
Mabuza told parliament on Wednesday.
The government’s response to the pandemic
has been rocked by corruption allegations in recent months. The Special
Investigating Unit (SIU) has been probing various suspicious Covid-19 contracts
in provinces such as Gauteng, the Eastern Cape and KwaZulu-Natal after
widespread allegations of nepotism and corruption largely linked to personal
protective equipment (PPE). The graft allegations have prompted the National
Treasury to look into the possible centralisation of procurement. Responding to
questions in the National Assembly on Wednesday, Mabuza, the chair of the
interministerial committee on vaccines, said the government has put in place
mechanisms to make it easier to report acts of corruption related to Covid-19
procurement.
Medical scheme members not keen to pay for others’ vaccines
Business Day 17 March 2021 - Only half of respondents back the government’s
proposal for the private sector to subsidise inoculation
Only half of SA’s medical scheme members
back a government proposal that they help fund Covid-19 vaccines for
non-members, according to a survey by the industry regulator. The results
reflect division within the medical schemes industry, which has yet to agree
with the government on how it might help fund the vaccine rollout. The most
likely mechanism is that medical schemes will pay a premium on the price the
government pays to vaccine manufacturers, but it is still not clear how the
premium will be set. The Treasury allocated R10.3bn for the government’s
vaccination programme in the budget, but indicated in February that it
anticipates some funding will come from the private sector. The government’s
vaccination strategy aims to inoculate 40-million adults, of whom an estimated
7.1-million belong to medical schemes.
HPCSA suspends 16 implicated in SIU corruption probe
Medical Brief 17 March 2021 - The Health Professions
Council of SA (HPCSA) has placed 16 employees on precautionary
suspension, after they were implicated in bribery and corruption involving the
expediting of registration processes.
The HPCSA said the
suspensions followed findings in an investigation into maladministration,
corruption and fraud that had been under way since 2019, notes News24.
The investigation, undertaken by the Special Investigating Unit, was
approved by President Cyril Ramaphosa at the request of the HPCSA.
Medicines regulator gives nod for Pfizer’s coronavirus shot to be administered in SA
Business Day 16 March 2021 - Section 21 authorisation is subject to close
monitoring of the safety and efficacy of the vaccine, Sahpra says
SA’s medicines
regulator has granted a Section 21 authorisation for the Pfizer/BioNTech
Covid-19 vaccine, clearing the way for the shot to be imported and administered
before it has been registered in SA. Section 21 of the Medicines and Related
Substances Act allows the SA Health Products Regulatory Authority (Sahpra) to
grant permission for the administration of unregistered medicines, provided
they have been approved by a stringent regulator such as the US Food and Drug
Administration or the European Medicines Authority. It has yet to finalise
Pfizer’s application to register its Covid-19 vaccine, branded Comirnaty. While Sahpra’s announcement means a
key regulatory hurdle has been cleared, it still remains an open question when
Pfizer’s vaccines will arrive in SA.
Better vaccines coming including ones that don’t use needles
Business Day 15 March 2021 - New treatments will add to the 10 already shown
to work within a year of Covid-19 being declared a pandemic
New Covid-19
vaccines, including ones that don’t require needles and can be stored at room
temperature, may be ready for use later this year or next year, the World
Health Organisation’s top scientist said. Six to eight new immunisations
may complete clinical studies and undergo regulatory review by the end of the
year, Soumya Swaminathan, the Geneva-based agency’s chief scientist, said in an
interview. New vaccines will add to the 10 already shown to work within a
year of Covid-19 being declared a pandemic.
Regular Covid-19 booster vaccines will be standard procedure
Business Day 15 March 2021 - The novel coronavirus mutates about once every
two weeks — slower than influenza or HIV, but enough to require tweaks to
vaccines
Regular booster
vaccines against the novel coronavirus will be needed because of mutations that
make it more transmissible and better able to evade human immunity, the head of
Britain’s effort to sequence the virus’s genomes told Reuters. The novel
coronavirus, which has killed 2.65-million people globally since it emerged in
China in late 2019, mutates about once every two weeks, slower than influenza
or HIV, but enough to require tweaks to vaccines. Sharon Peacock, who heads Covid-19 Genomics UK
(COG-UK) which has sequenced half of all the novel coronavirus genomes so far
mapped globally, said international co-operation was needed in the “cat and
mouse” battle with the virus.